https://translational-medicine.biomedcentral.com/articles/10.1186...

https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-024-06056-z

Synarta world leaders in Lysyl oxidase (LOX). Add diabetic nephropathy to the list as another multi billion market opportunity.

https://www.biospace.com/diabetic-nephropathy-market-estimated-to-reach-usd-14-572-9-million-by-2034-impelled-by-inflating-utilization-of-effective-medications

" In addition to SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs) like are emerging as powerful tools in the therapeutic arsenal against diabetic nephropathy. Finerenone has been shown to reduce albuminuria and slow the decline of kidney function by targeting key pathways involved in inflammation and fibrosis. The FIDELIO-DKD trial highlighted the efficacy of finerenone in significantly lowering the risk of kidney failure and cardiovascular morbidity in patients with chronic kidney disease associated with type 2 diabetes"

https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-reduce-risk-serious-kidney-and-heart-complications-adults-chronic-kidney-disease

More recently

https://www.bayer.com/media/en-us/finerenone-meets-primary-endpoint-in-phase-iii-finearts-hf-cardiovascular-outcomes-study-in-patients-with-heart-failure-with-mildly-reduced-or-preserved-ejection-fraction/
https://www.bayer.com/media/en-us/bayer-submits-application-to-us-fda-and-to-chinas-cde-for-new-indication-of-finerenone-for-patients-with-common-form-of-heart-failure-with-high-unmet-medical-need/

Bayor are forecasting $3 billion plus peak sales.